首页 > 最新文献

Journal of Chemotherapy最新文献

英文 中文
Intraperitoneal daptomycin dosing for peritonitis may be inadequate: a Monte Carlo simulation approach to optimize dosing and outcomes. 腹膜内注射达托霉素治疗腹膜炎的剂量可能不足:采用蒙特卡洛模拟法优化剂量和疗效。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-09-24 DOI: 10.1080/1120009X.2024.2407705
Taniya Charoensareerat, Tipvilai Taweepunturat, Vipavee Rodjun, Dhakrit Rungkitwattanakul, Sutthiporn Pattharachayakul, Aroonrut Lucksiri, Chonnikan Chutkrailert, Kittiwan Suksawat, Surisara Phasaprated, Susan J Lewis, Weerachai Chaijamorn

A two-compartmental mathematical pharmacokinetic model with first-order elimination of patients receiving CAPD of 4 exchanges for 6 h with 2 L of dialysate used in each cycle was developed to predict daptomycin disposition in 120 h of therapy. The pharmacodynamic target was plasma AUC/MIC equal to or greater than 666. The dose that achieved at least 90% of the probability of target attainment was defined as an optimal dose. Administering intraperitoneal 300 mg daily for 1 exchange daily regimen would be sufficient to treat peritonitis with S. aureus infection with MICs of 0.25 mg/L in patients undergoing CAPD. A higher dosage may be required for infections with a higher minimum inhibitory concentration. Pharmacodynamic targets and MICs significantly contributed to daptomycin doses in this setting. Clinical validation of our recommendations is recommended.

我们建立了一个两室数学药代动力学模型,对接受 6 小时 4 次换药、每个周期使用 2 升透析液的 CAPD 患者进行一阶消除,以预测达托霉素在治疗 120 小时内的处置情况。药效学目标是血浆 AUC/MIC 等于或大于 666。达到目标概率至少 90% 的剂量被定义为最佳剂量。在接受 CAPD 治疗的患者中,每天腹腔注射 300 毫克,每天换药 1 次,足以治疗 MIC 值为 0.25 毫克/升的金黄色葡萄球菌感染性腹膜炎。对于最低抑菌浓度较高的感染,可能需要更高的剂量。在这种情况下,药效学目标和 MIC 对达托霉素的剂量有重要影响。建议对我们的建议进行临床验证。
{"title":"Intraperitoneal daptomycin dosing for peritonitis may be inadequate: a Monte Carlo simulation approach to optimize dosing and outcomes.","authors":"Taniya Charoensareerat, Tipvilai Taweepunturat, Vipavee Rodjun, Dhakrit Rungkitwattanakul, Sutthiporn Pattharachayakul, Aroonrut Lucksiri, Chonnikan Chutkrailert, Kittiwan Suksawat, Surisara Phasaprated, Susan J Lewis, Weerachai Chaijamorn","doi":"10.1080/1120009X.2024.2407705","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2407705","url":null,"abstract":"<p><p>A two-compartmental mathematical pharmacokinetic model with first-order elimination of patients receiving CAPD of 4 exchanges for 6 h with 2 L of dialysate used in each cycle was developed to predict daptomycin disposition in 120 h of therapy. The pharmacodynamic target was plasma AUC/MIC equal to or greater than 666. The dose that achieved at least 90% of the probability of target attainment was defined as an optimal dose. Administering intraperitoneal 300 mg daily for 1 exchange daily regimen would be sufficient to treat peritonitis with <i>S. aureus</i> infection with MICs of 0.25 mg/L in patients undergoing CAPD. A higher dosage may be required for infections with a higher minimum inhibitory concentration. Pharmacodynamic targets and MICs significantly contributed to daptomycin doses in this setting. Clinical validation of our recommendations is recommended.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.9,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors of poor nutrition in non-small cell lung cancer patients after chemotherapy: cross-sectional study. 非小细胞肺癌患者化疗后营养不良的风险因素:横断面研究。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-09-22 DOI: 10.1080/1120009X.2024.2403183
Xiaohan Wang, Xiaodong Qu

This cross-sectional study aimed to analyze the associated factors of poor nutrition in non-small cell lung cancer (NSCLC) patients after chemotherapy. Concretely, 176 NSCLC patients who attended our hospital from June 2020 to December 2022 were enrolled. Standard-compliant patients were categorized into nutrition group (n = 38) and malnutrition group (n = 70) according to different nutrition statuses. Baseline characteristics and nutrition level were assessed. Associated factors of poor nutrition were analyzed by logistic regression analysis. There were obvious differences between nutrition group and malnutrition group in terms of age (P = 0.041), body mass index (BMI, p = 0.021), residence (P  = 0.023), per capita monthly income of family (P  = 0.023), tumor staging (P  = 0.017), Karnofsky (KPS) score (P  < 0.001), effect of chemotherapy (P  = 0.045), and nutrition support before chemotherapy only (P  = 0.023) and perichemotherapy (P = 0.011). The higher proportion of NSCLC patients was found in malnutrition group relative to nutrition group in terms of having poor nutritional cognition (67.14% vs. 47.37%, P  = 0.045), and lacking access to vitamins (65.71% vs. 44.74%, P  = 0.047) and trace elements (57.14% vs. 36.84%, P  = 0.044). BMI <18.5 (OR = 3.707, P = 0.007, 95%CI (1.434-9.586)), residence in village (OR = 3.426, P = 0.013, 95%CI (1.291-9.092)), and KPS score ≤70 (OR = 7.608, P < 0.001, 95%CI (2.842-20.367)) were associated factors for poor nutrition. Collectively, BMI, residence, and KPS score were associated factors of poor nutrition in NSCLC patients after chemotherapy.

本横断面研究旨在分析非小细胞肺癌(NSCLC)患者化疗后营养不良的相关因素。具体而言,研究人员选取了2020年6月至2022年12月期间在我院就诊的176名NSCLC患者。根据不同的营养状况将符合标准的患者分为营养组(38 人)和营养不良组(70 人)。评估基线特征和营养水平。通过逻辑回归分析,对营养不良的相关因素进行了分析。营养组与营养不良组在年龄(P = 0.041)、体重指数(BMI,P = 0.021)、居住地(P = 0.023)、家庭人均月收入(P = 0.023)、肿瘤分期(P = 0.017)、Karnofsky(KPS)评分(P 0.001)、化疗效果(P = 0.045)、仅化疗前(P = 0.023)和围化疗期(P = 0.011)的营养支持。与营养组相比,营养不良组 NSCLC 患者营养认知能力差(67.14% 对 47.37%,P = 0.045)、缺乏维生素(65.71% 对 44.74%,P = 0.047)和微量元素(57.14% 对 36.84%,P = 0.044)的比例更高。体重指数 CI (1.434-9.586))、居住地(OR = 3.426,P = 0.013,95%CI (1.291-9.092))和 KPS 评分≤70(OR = 7.608,P CI (2.842-20.367))是营养不良的相关因素。总而言之,体重指数、居住地和KPS评分是NSCLC患者化疗后营养不良的相关因素。
{"title":"Risk factors of poor nutrition in non-small cell lung cancer patients after chemotherapy: cross-sectional study.","authors":"Xiaohan Wang, Xiaodong Qu","doi":"10.1080/1120009X.2024.2403183","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2403183","url":null,"abstract":"<p><p>This cross-sectional study aimed to analyze the associated factors of poor nutrition in non-small cell lung cancer (NSCLC) patients after chemotherapy. Concretely, 176 NSCLC patients who attended our hospital from June 2020 to December 2022 were enrolled. Standard-compliant patients were categorized into nutrition group (<i>n</i> = 38) and malnutrition group (<i>n</i> = 70) according to different nutrition statuses. Baseline characteristics and nutrition level were assessed. Associated factors of poor nutrition were analyzed by logistic regression analysis. There were obvious differences between nutrition group and malnutrition group in terms of age (P = 0.041), body mass index (BMI, <i>p</i> = 0.021), residence (P  = 0.023), per capita monthly income of family (P  = 0.023), tumor staging (P  = 0.017), Karnofsky (KPS) score (P <i> <</i> 0.001), effect of chemotherapy (P  = 0.045), and nutrition support before chemotherapy only (P  = 0.023) and perichemotherapy (P = 0.011). The higher proportion of NSCLC patients was found in malnutrition group relative to nutrition group in terms of having poor nutritional cognition (67.14% vs. 47.37%, P  = 0.045), and lacking access to vitamins (65.71% vs. 44.74%, P  = 0.047) and trace elements (57.14% vs. 36.84%, P  = 0.044). BMI <18.5 (OR = 3.707, P = 0.007, 95%<i>CI</i> (1.434-9.586)), residence in village (OR = 3.426, P = 0.013, 95%<i>CI</i> (1.291-9.092)), and KPS score ≤70 (OR = 7.608, P < 0.001, 95%<i>CI</i> (2.842-20.367)) were associated factors for poor nutrition. Collectively, BMI, residence, and KPS score were associated factors of poor nutrition in NSCLC patients after chemotherapy.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.9,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Colistin resistance among the Gram-negative nosocomial pathogens in India: a systematic review and meta-analysis. 印度革兰氏阴性医院病原体对可乐定的耐药性:系统回顾和荟萃分析。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-09-20 DOI: 10.1080/1120009X.2024.2405355
Sambit K Dwibedy, Indira Padhy, Aditya K Panda, Saswat S Mohapatra

The rapid rise of nosocomial infections and the growing ineffectiveness of frontline antibiotics against Gram-negative bacteria (GNB) have put the healthcare sector under unprecedented stress. In this scenario, colistin, an antibiotic of the polymyxin class, has become the last resort treatment option. However, the unrestricted use of colistin in the preceding decades has led to the emergence of colistin-resistant (ColR) bacterial strains. Unfortunately, comprehensive data on the prevalence of ColR nosocomial pathogens in India are scarce. This study was conducted to address this information gap. A systematic review and meta-analysis were conducted to determine the prevalence of ColR among the nosocomial GNB species in India and their geographical distribution. A systematic search of the online databases was performed and eligible studies meeting the inclusion criteria were used for qualitative synthesis. The combined event rate and 95% confidence interval were estimated using a forest plot with a random-effect model. Cochrane Q statistics and I2 statistics were used to detect possible heterogeneity. From a total of 1865 retrieved records from 4 databases, 33 studies were included in the study. Among the most common nosocomial pathogens, Klebsiella pneumoniae showed a rate of ColR at 16.1% (95% CI: 10.1 to 24.6), followed by Pseudomonas aeruginosa (13.3%) (95% CI: 9.1 to 19.2), Acinetobacter baumannii (10%) (95% CI: 7.5 to 13.2), and Escherichia coli (7.8%) (95% CI: 5.3 to 11.2). Interestingly, our analysis revealed that Enterobacter cloacae have the highest rate of ColR at 27.9% (95% CI: 12.7 to 50.9). The results indicate that the prevalence of ColR nosocomial pathogens vary among regions and over time; however, continuous monitoring, and sustained efforts are crucial to ensure the effectiveness of colistin antibiotic.

随着院内感染的迅速增加,一线抗生素对革兰氏阴性菌(GNB)的疗效越来越差,医疗保健行业面临着前所未有的压力。在这种情况下,多粘菌素类抗生素可乐菌素已成为最后的治疗选择。然而,在过去几十年中,由于不加限制地使用可乐定,导致耐可乐定(ColR)细菌菌株的出现。遗憾的是,有关印度 ColR 非医院病原体流行情况的全面数据非常稀少。本研究就是为了填补这一信息空白而进行的。研究人员进行了系统回顾和荟萃分析,以确定 ColR 在印度病原性 GNB 菌种中的流行情况及其地理分布。研究人员对在线数据库进行了系统性检索,并对符合纳入标准的研究进行了定性综合。采用随机效应模型的森林图估算综合事件发生率和 95% 置信区间。Cochrane Q 统计量和 I2 统计量用于检测可能存在的异质性。从 4 个数据库中共检索到 1865 条记录,其中 33 项研究被纳入研究范围。在最常见的院内病原体中,肺炎克雷伯菌的 ColR 率为 16.1%(95% CI:10.1 至 24.6),其次是铜绿假单胞菌(13.3%)(95% CI:9.1 至 19.2)、鲍曼不动杆菌(10%)(95% CI:7.5 至 13.2)和大肠埃希菌(7.8%)(95% CI:5.3 至 11.2)。有趣的是,我们的分析显示,泄殖腔肠杆菌的 ColR 感染率最高,为 27.9%(95% CI:12.7 至 50.9)。这些结果表明,不同地区和不同时间段,ColR 非病原菌的流行率各不相同;然而,持续监测和不断努力对于确保可乐定抗生素的有效性至关重要。
{"title":"Colistin resistance among the Gram-negative nosocomial pathogens in India: a systematic review and meta-analysis.","authors":"Sambit K Dwibedy, Indira Padhy, Aditya K Panda, Saswat S Mohapatra","doi":"10.1080/1120009X.2024.2405355","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2405355","url":null,"abstract":"<p><p>The rapid rise of nosocomial infections and the growing ineffectiveness of frontline antibiotics against Gram-negative bacteria (GNB) have put the healthcare sector under unprecedented stress. In this scenario, colistin, an antibiotic of the polymyxin class, has become the last resort treatment option. However, the unrestricted use of colistin in the preceding decades has led to the emergence of colistin-resistant (Col<sup>R</sup>) bacterial strains. Unfortunately, comprehensive data on the prevalence of Col<sup>R</sup> nosocomial pathogens in India are scarce. This study was conducted to address this information gap. A systematic review and meta-analysis were conducted to determine the prevalence of Col<sup>R</sup> among the nosocomial GNB species in India and their geographical distribution. A systematic search of the online databases was performed and eligible studies meeting the inclusion criteria were used for qualitative synthesis. The combined event rate and 95% confidence interval were estimated using a forest plot with a random-effect model. Cochrane Q statistics and <i>I<sup>2</sup></i> statistics were used to detect possible heterogeneity. From a total of 1865 retrieved records from 4 databases, 33 studies were included in the study. Among the most common nosocomial pathogens<i>, Klebsiella pneumoniae</i> showed a rate of Col<sup>R</sup> at 16.1% (95% CI: 10.1 to 24.6), followed by <i>Pseudomonas aeruginosa</i> (13.3%) (95% CI: 9.1 to 19.2), <i>Acinetobacter baumannii</i> (10%) (95% CI: 7.5 to 13.2), and <i>Escherichia coli</i> (7.8%) (95% CI: 5.3 to 11.2). Interestingly, our analysis revealed that <i>Enterobacter cloacae</i> have the highest rate of Col<sup>R</sup> at 27.9% (95% CI: 12.7 to 50.9). The results indicate that the prevalence of Col<sup>R</sup> nosocomial pathogens vary among regions and over time; however, continuous monitoring, and sustained efforts are crucial to ensure the effectiveness of colistin antibiotic.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-13"},"PeriodicalIF":1.9,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of postsurgical adjuvant chemotherapy timing on outcomes in patients with pancreatic cancer - a systematic review and meta-analysis. 手术后辅助化疗时机对胰腺癌患者预后的影响--系统综述和荟萃分析。
IF 1.8 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-09-17 DOI: 10.1080/1120009x.2024.2402175
Longlan Zhou,Lin Zhang
To assess the association between the timing of postsurgical adjuvant chemotherapy and overall survival (OS) and disease-free survival (DFS) in patients with pancreatic cancer (PC). Literature search of PubMed, EMBASE, and Scopus databases was done for randomized controlled trials (RCTs) or observational studies (cohort studies, case-control studies), reporting outcomes of adult PC patients (aged 18 and above) who underwent surgery and received adjuvant chemotherapy at different time points after the operation. Pooled effect sizes were quantified and reported as hazard ratio (HR). The primary outcomes were OS and DFS. A random effects model to was used account for potential variability across studies. Sixteen studies were included. There was no significant difference between early and delayed initiation of adjuvant chemotherapy in terms of OS (HR 1.03, 95% CI: 0.98, 1.08) and DFS (HR 1.09, 95% CI: 0.91, 1.31). Subgroup analyses based on tumour stage, sample size, and the number of chemotherapeutic agents used did not reveal significant associations. Delayed initiation was associated with reduced OS in patients with well- to moderately differentiated tumours, with the confidence intervals approaching statistical significance (HR 1.12, 95% CI: 1.00,1.25). There was no significant association between the timing of postoperative adjuvant chemotherapy initiation and OS and DFS in patients with pancreatic cancer. These findings underscore the importance of optimizing treatment strategies and suggest that clinicians need to focus on other critical aspects such as drug selection, dosage, and patient-specific factors that might substantially impact treatment efficacy.
目的:评估胰腺癌(PC)患者手术后辅助化疗的时机与总生存期(OS)和无病生存期(DFS)之间的关系。我们在 PubMed、EMBASE 和 Scopus 数据库中检索了随机对照试验(RCT)或观察性研究(队列研究、病例对照研究),这些研究报告了成年 PC 患者(18 岁及以上)接受手术并在术后不同时间点接受辅助化疗的结果。汇总的效应大小被量化并以危险比(HR)的形式报告。主要结果为OS和DFS。研究采用随机效应模型,以考虑不同研究之间的潜在差异。共纳入 16 项研究。就OS(HR 1.03,95% CI:0.98, 1.08)和DFS(HR 1.09,95% CI:0.91, 1.31)而言,早期和延迟开始辅助化疗没有明显差异。基于肿瘤分期、样本大小和所用化疗药物数量的亚组分析未显示出显著的相关性。在分化良好至中度的肿瘤患者中,延迟开始化疗与OS降低有关,置信区间接近统计学意义(HR 1.12,95% CI:1.00,1.25)。胰腺癌患者术后辅助化疗的开始时间与OS和DFS之间没有明显关系。这些发现强调了优化治疗策略的重要性,并提示临床医生需要关注其他关键方面,如药物选择、剂量和可能对疗效产生重大影响的患者特异性因素。
{"title":"Effect of postsurgical adjuvant chemotherapy timing on outcomes in patients with pancreatic cancer - a systematic review and meta-analysis.","authors":"Longlan Zhou,Lin Zhang","doi":"10.1080/1120009x.2024.2402175","DOIUrl":"https://doi.org/10.1080/1120009x.2024.2402175","url":null,"abstract":"To assess the association between the timing of postsurgical adjuvant chemotherapy and overall survival (OS) and disease-free survival (DFS) in patients with pancreatic cancer (PC). Literature search of PubMed, EMBASE, and Scopus databases was done for randomized controlled trials (RCTs) or observational studies (cohort studies, case-control studies), reporting outcomes of adult PC patients (aged 18 and above) who underwent surgery and received adjuvant chemotherapy at different time points after the operation. Pooled effect sizes were quantified and reported as hazard ratio (HR). The primary outcomes were OS and DFS. A random effects model to was used account for potential variability across studies. Sixteen studies were included. There was no significant difference between early and delayed initiation of adjuvant chemotherapy in terms of OS (HR 1.03, 95% CI: 0.98, 1.08) and DFS (HR 1.09, 95% CI: 0.91, 1.31). Subgroup analyses based on tumour stage, sample size, and the number of chemotherapeutic agents used did not reveal significant associations. Delayed initiation was associated with reduced OS in patients with well- to moderately differentiated tumours, with the confidence intervals approaching statistical significance (HR 1.12, 95% CI: 1.00,1.25). There was no significant association between the timing of postoperative adjuvant chemotherapy initiation and OS and DFS in patients with pancreatic cancer. These findings underscore the importance of optimizing treatment strategies and suggest that clinicians need to focus on other critical aspects such as drug selection, dosage, and patient-specific factors that might substantially impact treatment efficacy.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":"29 1","pages":"1-11"},"PeriodicalIF":1.8,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142249294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reversible chemoresistance of pancreatic cancer grown as spheroids. 球形胰腺癌的可逆化疗抗药性
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-09-16 DOI: 10.1080/1120009X.2024.2402177
Yoshihisa Matsushita, Alexis Norris, Yi Zhong, Asma Begum, Hong Liang, Marija Debeljak, Nicole Anders, Michael Goggins, Zeshaan A Rasheed, Ralph H Hruban, Christopher L Wolfgang, Elizabeth D Thompson, Michelle A Rudek, Jun O Liu, Leslie Cope, James R Eshleman

Better in vitro models are needed to identify active drugs to treat pancreatic adenocarcinoma (PAC) patients. We used 3D hanging drop cultures to produce spheroids from five PAC cell lines and tested nine FDA-approved drugs in clinical use. All PAC cell lines in 2D culture were sensitive to three drugs (gemcitabine, docetaxel and nab-paclitaxel), however most PAC (4/5) 3D spheroids acquired profound chemoresistance even at 10 µM. In contrast, spheroids retained sensitivity to the investigational drug triptolide, which induced apoptosis. The acquired chemoresistance was also transiently retained when cells were placed back into 2D culture and six genes potentially associated with chemoresistance were identified by microarray and confirmed using quantitative RT-PCR. We demonstrate the additive effect of gemcitabine and erlotinib, from the 12 different combinations of nine drugs tested. This comprehensive study shows spheroids as a useful multicellular model of PAC for drug screening and elucidating the mechanism of chemoresistance.

需要更好的体外模型来确定治疗胰腺腺癌(PAC)患者的活性药物。我们使用三维悬滴培养法从五个 PAC 细胞系中培养出球形细胞,并测试了九种经 FDA 批准用于临床的药物。二维培养的所有 PAC 细胞系都对三种药物(吉西他滨、多西他赛和纳布-紫杉醇)敏感,但大多数 PAC(4/5)的三维球形细胞即使在 10 µM 的浓度下也会产生严重的化疗耐药性。与此相反,球体对诱导细胞凋亡的研究药物三苯氧胺保持敏感性。当把细胞放回二维培养时,获得的化疗抗性也会暂时保留,通过微阵列确定了六个可能与化疗抗性相关的基因,并通过定量 RT-PCR 进行了确认。我们展示了吉西他滨和厄洛替尼在九种药物的 12 种不同组合测试中的叠加效应。这项综合研究表明,球形体是一种有用的多细胞PAC模型,可用于药物筛选和阐明化疗耐药机制。
{"title":"Reversible chemoresistance of pancreatic cancer grown as spheroids.","authors":"Yoshihisa Matsushita, Alexis Norris, Yi Zhong, Asma Begum, Hong Liang, Marija Debeljak, Nicole Anders, Michael Goggins, Zeshaan A Rasheed, Ralph H Hruban, Christopher L Wolfgang, Elizabeth D Thompson, Michelle A Rudek, Jun O Liu, Leslie Cope, James R Eshleman","doi":"10.1080/1120009X.2024.2402177","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2402177","url":null,"abstract":"<p><p>Better <i>in vitro</i> models are needed to identify active drugs to treat pancreatic adenocarcinoma (PAC) patients. We used 3D hanging drop cultures to produce spheroids from five PAC cell lines and tested nine FDA-approved drugs in clinical use. All PAC cell lines in 2D culture were sensitive to three drugs (gemcitabine, docetaxel and nab-paclitaxel), however most PAC (4/5) 3D spheroids acquired profound chemoresistance even at 10 µM. In contrast, spheroids retained sensitivity to the investigational drug triptolide, which induced apoptosis. The acquired chemoresistance was also transiently retained when cells were placed back into 2D culture and six genes potentially associated with chemoresistance were identified by microarray and confirmed using quantitative RT-PCR. We demonstrate the additive effect of gemcitabine and erlotinib, from the 12 different combinations of nine drugs tested. This comprehensive study shows spheroids as a useful multicellular model of PAC for drug screening and elucidating the mechanism of chemoresistance.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-15"},"PeriodicalIF":1.9,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Signaling effect, combinations, and clinical applications of triciribine. 三尖杉酯碱的信号效应、组合和临床应用。
IF 1.8 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-09-14 DOI: 10.1080/1120009x.2024.2403050
Shinichiro Takahashi
Triciribine (TCN) is a tricyclic nucleoside. Its synthesis was first described in 1971. Subsequent studies have indicated that TCN plays a role in inhibiting DNA synthesis and was revealed to possess a higher selectivity for Akt. Although a single dose of TCN demonstrated limited activity in solid tumors at the clinical level, combinations of TCN with various agents, such as specific inhibitors, tyrosine kinase inhibitor dasatinib, ErbB inhibitor tipifarnib, IGF1-R inhibitor NVP-AEW541, mTORC1 inhibitor RAD-001, TNF-related apoptosis-inducing ligand, PPARγ agonist, 1,25(OH)2D3, gemcitabine, and paclitaxel, have been reported to be efficient against various malignancies such as pancreatic, breast, prostate cancer, insulinoma, gut neuroendocrine tumor, and hepatocellular carcinoma at the preclinical level. Other than malignancies, through Akt inhibition activity, TCN has also been demonstrated potential for treating lung injuries, including those encountered in COVID-19 infections.
曲克利宾(TCN)是一种三环核苷。1971 年首次描述了它的合成。随后的研究表明,TCN 具有抑制 DNA 合成的作用,并发现它对 Akt 具有更高的选择性。虽然单剂量 TCN 在临床上对实体瘤的活性有限,但 TCN 与多种药物的联合使用,如特异性抑制剂、酪氨酸激酶抑制剂达沙替尼、ErbB 抑制剂替尼法尼、IGF1-R 抑制剂 NVP-AEW541、mTORC1 抑制剂 RAD-001、TNF 相关凋亡诱导配体、PPARγ 激动剂、1,25(OH)2D3、吉西他滨和紫杉醇,这些药物在临床前水平上已被报道能有效对抗各种恶性肿瘤,如胰腺癌、乳腺癌、前列腺癌、胰岛素瘤、肠道神经内分泌瘤和肝细胞癌。除恶性肿瘤外,通过 Akt 抑制活性,TCN 还被证明具有治疗肺损伤(包括 COVID-19 感染中出现的肺损伤)的潜力。
{"title":"Signaling effect, combinations, and clinical applications of triciribine.","authors":"Shinichiro Takahashi","doi":"10.1080/1120009x.2024.2403050","DOIUrl":"https://doi.org/10.1080/1120009x.2024.2403050","url":null,"abstract":"Triciribine (TCN) is a tricyclic nucleoside. Its synthesis was first described in 1971. Subsequent studies have indicated that TCN plays a role in inhibiting DNA synthesis and was revealed to possess a higher selectivity for Akt. Although a single dose of TCN demonstrated limited activity in solid tumors at the clinical level, combinations of TCN with various agents, such as specific inhibitors, tyrosine kinase inhibitor dasatinib, ErbB inhibitor tipifarnib, IGF1-R inhibitor NVP-AEW541, mTORC1 inhibitor RAD-001, TNF-related apoptosis-inducing ligand, PPARγ agonist, 1,25(OH)2D3, gemcitabine, and paclitaxel, have been reported to be efficient against various malignancies such as pancreatic, breast, prostate cancer, insulinoma, gut neuroendocrine tumor, and hepatocellular carcinoma at the preclinical level. Other than malignancies, through Akt inhibition activity, TCN has also been demonstrated potential for treating lung injuries, including those encountered in COVID-19 infections.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":"1 1","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142249295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma. 比较舒尼替尼和帕唑帕尼对晚期非透明肾细胞癌患者的疗效。
IF 1.8 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-09-10 DOI: 10.1080/1120009x.2024.2403051
Hasan Cagri Yildirim,Ertuğrul Bayram,Elvin Chalabiyev,Nargız Majidova,Tugay Avci,Halil Göksel Güzel,Caner Kapar,Mehmet Uzun,Perihan Perkin,Fahri Akgül,Saadet Sim Yildirim,Seda Sali,Anil Yildiz,Seher Nazli Kazaz,Engin Hendem,Murat Arcagok,Gulnihal Tufan,Umit Yildirim,Omer Faruk Akgul,Çagatay Arslan,Hakan Taban,Eren Sahin,Melek Caglayan,Ramazan Esen,Berna Öksüzoğlu,Deniz Can Guven,Muhammet Ali Kaplan,Murat Araz,Mert Basaran,Erdem Cubukcu,Erhan Gokmen,Irfan Cicin,Efnan Algin,Huseyin Salih Semiz,Deniz Tural,Banu Ozturk,Atike Pinar Erdogan,Murat Sari,Oguz Kara,Mustafa Erman
Non-clear cell renal cell carcinoma (non-ccRCC) is a highly heterogeneous disease group, accounting for approximately 25% of all RCC cases. Due to its rarity and especially heterogeneity, phase III trial data is limited and treatment options generally follow those of clear cell RCC. In the literature, there exists a number of studies with sunitinib, cabozantinib, and everolimus, but data on the efficacy of pazopanib are limited. Our aim in this study was to compare the efficacy of pazopanib and sunitinib, in a multicenter retrospective cohort of non-ccRCC patients. Our study included patients diagnosed with non-ccRCC who received pazopanib or sunitinib treatment as first-line therapy from 22 tertiary hospitals. We compared the progression-free survival (PFS), overall survival (OS), and response rates of pazopanib and sunitinib treatments. Additionally, we investigated prognostic factors in non-ccRCC. PFS and response rates of sunitinib and pazopanib were found to be similar, while a numerical difference was observed in OS. Being 65 years and older, being in the intermediate or poor risk group according to the International Metastatic Renal Cell Carcinoma Database Consortium, having liver metastases, presence of a sarcomatoid component, and having de novo metastatic disease were found to be significantly associated with shorter PFS. Pazopanib treatment appears to have similar efficacy in the treatment of non-ccRCC compared to sunitinib. Though randomized controlled trials are lacking and will probably be never be available, we suggest that pazopanib could be a preferred agent like sunitinib and cabozantinib.
非透明细胞肾细胞癌(non-ccRCC)是一种高度异质性疾病,约占所有 RCC 病例的 25%。由于其罕见性,尤其是异质性,III 期试验数据有限,治疗方案通常沿用透明细胞 RCC 的治疗方案。在文献中,有一些关于舒尼替尼、卡博赞替尼和依维莫司的研究,但关于帕唑帕尼疗效的数据却很有限。本研究的目的是在非ccRCC患者的多中心回顾性队列中比较帕唑帕尼和舒尼替尼的疗效。我们的研究纳入了来自22家三级医院、接受帕唑帕尼或舒尼替尼一线治疗的非ccRCC患者。我们比较了帕唑帕尼和舒尼替尼治疗的无进展生存期(PFS)、总生存期(OS)和反应率。此外,我们还调查了非ccRCC的预后因素。结果发现,舒尼替尼和帕唑帕尼的治疗后生存期和反应率相似,而在治疗后生存期方面则存在数字差异。根据国际转移性肾细胞癌数据库联盟(International Metastatic Renal Cell Carcinoma Database Consortium),65岁及以上、中危或低危组、肝转移、肉瘤样成分和新发转移性疾病与较短的PFS显著相关。与舒尼替尼相比,帕唑帕尼治疗非ccRCC的疗效似乎相似。虽然目前还缺乏随机对照试验,而且很可能永远也不会有随机对照试验,但我们建议帕唑帕尼可以像舒尼替尼和卡博替尼一样成为首选药物。
{"title":"Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma.","authors":"Hasan Cagri Yildirim,Ertuğrul Bayram,Elvin Chalabiyev,Nargız Majidova,Tugay Avci,Halil Göksel Güzel,Caner Kapar,Mehmet Uzun,Perihan Perkin,Fahri Akgül,Saadet Sim Yildirim,Seda Sali,Anil Yildiz,Seher Nazli Kazaz,Engin Hendem,Murat Arcagok,Gulnihal Tufan,Umit Yildirim,Omer Faruk Akgul,Çagatay Arslan,Hakan Taban,Eren Sahin,Melek Caglayan,Ramazan Esen,Berna Öksüzoğlu,Deniz Can Guven,Muhammet Ali Kaplan,Murat Araz,Mert Basaran,Erdem Cubukcu,Erhan Gokmen,Irfan Cicin,Efnan Algin,Huseyin Salih Semiz,Deniz Tural,Banu Ozturk,Atike Pinar Erdogan,Murat Sari,Oguz Kara,Mustafa Erman","doi":"10.1080/1120009x.2024.2403051","DOIUrl":"https://doi.org/10.1080/1120009x.2024.2403051","url":null,"abstract":"Non-clear cell renal cell carcinoma (non-ccRCC) is a highly heterogeneous disease group, accounting for approximately 25% of all RCC cases. Due to its rarity and especially heterogeneity, phase III trial data is limited and treatment options generally follow those of clear cell RCC. In the literature, there exists a number of studies with sunitinib, cabozantinib, and everolimus, but data on the efficacy of pazopanib are limited. Our aim in this study was to compare the efficacy of pazopanib and sunitinib, in a multicenter retrospective cohort of non-ccRCC patients. Our study included patients diagnosed with non-ccRCC who received pazopanib or sunitinib treatment as first-line therapy from 22 tertiary hospitals. We compared the progression-free survival (PFS), overall survival (OS), and response rates of pazopanib and sunitinib treatments. Additionally, we investigated prognostic factors in non-ccRCC. PFS and response rates of sunitinib and pazopanib were found to be similar, while a numerical difference was observed in OS. Being 65 years and older, being in the intermediate or poor risk group according to the International Metastatic Renal Cell Carcinoma Database Consortium, having liver metastases, presence of a sarcomatoid component, and having de novo metastatic disease were found to be significantly associated with shorter PFS. Pazopanib treatment appears to have similar efficacy in the treatment of non-ccRCC compared to sunitinib. Though randomized controlled trials are lacking and will probably be never be available, we suggest that pazopanib could be a preferred agent like sunitinib and cabozantinib.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":"59 1","pages":"1-12"},"PeriodicalIF":1.8,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142187338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TRIM24/ZFX affects the stemness and resistance to 5-FU of colorectal cancer cells. TRIM24/ZFX影响结直肠癌细胞的干性和对5-FU的耐药性。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-09-02 DOI: 10.1080/1120009X.2024.2376422
Xuming Yao, Zhiping Yang, Guoxin Hou, Jialu Jiang, Lvbin Wang, Jin Jiang

Colorectal cancer (CRC) is the second leading cause of cancer death, and about 10% of all malignancies are CRC. Cancer stem cells are considered main culprits in CRC treatment resistance and disease recurrence. This study explored the effects of tripartite motif containing 24 (TRIM24) and zinc finger protein, X-linked (ZFX) on CRC cell stemness and 5-FU resistance. A 5-FU-resistant cell line (HT29-5-FU) was constructed for functional analysis of CRC 5-FU-resistant cells. qRT-PCR and western blot (WB) were employed to analyze mRNA and protein levels of ZFX in 5-FU resistant cells and sensitive cells. WB was also utilized to analyze the surface markers of stem cells in each group. CCK-8 assay determined the IC50 values of different cell groups treated with 5-FU. The sphere-forming ability of cells in each group was determined using tumor sphere assay. Dual-luciferase reporter gene assay validated binding of ZFX to TRIM24. ZFX was highly expressed in HT29-5-FU cells. Silencing ZFX significantly reduced the 5-FU resistance and IC50 value of HT29-5-FU cells, and the surface markers and cell sphere-forming ability of stem cells were also significantly reduced. The function of HT29 cells was opposite when ZFX was overexpressed. In CRC cells, TRIM24 was an upstream transcription factor of ZFX, and they interacted with each other. TRIM24 activated the expression of ZFX to influence the stemness and 5-FU resistance of cells. The TRIM24/ZFX regulatory axis affected the stemness of CRC cells and their sensitivity to 5-FU, providing potential drug targets for novel therapeutic avenues for CRC.

结肠直肠癌(CRC)是导致癌症死亡的第二大原因,约有10%的恶性肿瘤是CRC。癌症干细胞被认为是导致 CRC 耐药性和疾病复发的罪魁祸首。本研究探讨了含三方基序24(TRIM24)和锌指蛋白X连锁(ZFX)对CRC细胞干性和5-FU耐药性的影响。为了对 CRC 5-FU 耐药细胞进行功能分析,研究人员构建了一个 5-FU 耐药细胞系(HT29-5-FU),并采用 qRT-PCR 和 Western blot (WB) 技术分析 5-FU 耐药细胞和敏感细胞中 ZFX 的 mRNA 和蛋白水平。还利用WB分析了各组干细胞的表面标记物。CCK-8试验测定了不同细胞组在5-FU处理下的IC50值。肿瘤球试验测定了各组细胞的成球能力。双荧光素酶报告基因检测验证了ZFX与TRIM24的结合。ZFX在HT29-5-FU细胞中高表达。沉默ZFX能明显降低HT29-5-FU细胞对5-FU的耐药性和IC50值,干细胞的表面标志物和细胞球形成能力也明显降低。当ZFX过表达时,HT29细胞的功能则相反。在 CRC 细胞中,TRIM24 是 ZFX 的上游转录因子,它们之间存在相互作用。TRIM24激活ZFX的表达,从而影响细胞的干性和对5-FU的耐受性。TRIM24/ZFX调控轴影响了CRC细胞的干性及其对5-FU的敏感性,为CRC的新型治疗途径提供了潜在的药物靶点。
{"title":"TRIM24/ZFX affects the stemness and resistance to 5-FU of colorectal cancer cells.","authors":"Xuming Yao, Zhiping Yang, Guoxin Hou, Jialu Jiang, Lvbin Wang, Jin Jiang","doi":"10.1080/1120009X.2024.2376422","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2376422","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is the second leading cause of cancer death, and about 10% of all malignancies are CRC. Cancer stem cells are considered main culprits in CRC treatment resistance and disease recurrence. This study explored the effects of tripartite motif containing 24 (TRIM24) and zinc finger protein, X-linked (ZFX) on CRC cell stemness and 5-FU resistance. A 5-FU-resistant cell line (HT29-5-FU) was constructed for functional analysis of CRC 5-FU-resistant cells. qRT-PCR and western blot (WB) were employed to analyze mRNA and protein levels of ZFX in 5-FU resistant cells and sensitive cells. WB was also utilized to analyze the surface markers of stem cells in each group. CCK-8 assay determined the IC<sub>50</sub> values of different cell groups treated with 5-FU. The sphere-forming ability of cells in each group was determined using tumor sphere assay. Dual-luciferase reporter gene assay validated binding of ZFX to TRIM24. ZFX was highly expressed in HT29-5-FU cells. Silencing ZFX significantly reduced the 5-FU resistance and IC<sub>50</sub> value of HT29-5-FU cells, and the surface markers and cell sphere-forming ability of stem cells were also significantly reduced. The function of HT29 cells was opposite when ZFX was overexpressed. In CRC cells, TRIM24 was an upstream transcription factor of ZFX, and they interacted with each other. TRIM24 activated the expression of ZFX to influence the stemness and 5-FU resistance of cells. The TRIM24/ZFX regulatory axis affected the stemness of CRC cells and their sensitivity to 5-FU, providing potential drug targets for novel therapeutic avenues for CRC.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.9,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances in caspase-3, breast cancer, and traditional Chinese medicine: a review. 半胱氨酸天冬氨酸蛋白酶-3、乳腺癌症和中药的最新进展:综述。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-09-01 Epub Date: 2023-11-07 DOI: 10.1080/1120009X.2023.2278014
He Dou, Ping Yang Yu, Yu Qi Liu, Yue Zhu, Fu Cheng Li, You Yu Wang, Xing Yan Chen, Min Xiao

Caspases (cysteinyl aspartate-specific proteinases) are a group of structurally similar proteases in the cytoplasm that can be involved in cell differentiation, programmed death, proliferation, and inflammatory generation. Experts have found that caspase-3 can serve as a terminal splicing enzyme in apoptosis and participate in the mechanism by which cytotoxic drugs kill cancer cells. Breast cancer (BC) has become the most common cancer among women worldwide, posing a severe threat to their lives. Finding new therapeutic targets for BC is the primary task of contemporary physicians. Numerous studies have revealed the close association between caspase-3 expression and BC. Caspase-3 is essential in BC's occurrence, invasion, and metastasis. In addition, Caspase-3 exerts anticancer effects by regulating cell death mechanisms. Traditional Chinese medicine acting through caspase-3 expression is increasingly used in clinical treatment. This review summarizes the biological mechanism of caspase-3 and research progress on BC. It introduces a variety of traditional Chinese medicine related to caspase-3 to provide new ideas for the clinical treatment of BC.

半胱天冬氨酸蛋白酶(半胱氨酸天冬氨酸特异性蛋白酶)是细胞质中一组结构相似的蛋白酶,可参与细胞分化、程序性死亡、增殖和炎症生成。专家发现,胱天蛋白酶-3可以作为细胞凋亡的末端剪接酶,参与细胞毒性药物杀死癌症细胞的机制。癌症(BC)已成为全球女性中最常见的癌症,对她们的生命构成严重威胁。为BC寻找新的治疗靶点是当代医生的首要任务。大量研究揭示了胱天蛋白酶-3的表达与BC之间的密切联系。Caspase-3在BC的发生、侵袭和转移中起重要作用。此外,Caspase-3通过调节细胞死亡机制发挥抗癌作用。中药通过胱天蛋白酶-3的表达发挥作用,在临床治疗中得到越来越多的应用。本文综述了胱天蛋白酶-3的生物学机制及对BC的研究进展。介绍了多种与胱天蛋白酶-3相关的中药,为BC的临床治疗提供新思路。
{"title":"Recent advances in caspase-3, breast cancer, and traditional Chinese medicine: a review.","authors":"He Dou, Ping Yang Yu, Yu Qi Liu, Yue Zhu, Fu Cheng Li, You Yu Wang, Xing Yan Chen, Min Xiao","doi":"10.1080/1120009X.2023.2278014","DOIUrl":"10.1080/1120009X.2023.2278014","url":null,"abstract":"<p><p>Caspases (cysteinyl aspartate-specific proteinases) are a group of structurally similar proteases in the cytoplasm that can be involved in cell differentiation, programmed death, proliferation, and inflammatory generation. Experts have found that caspase-3 can serve as a terminal splicing enzyme in apoptosis and participate in the mechanism by which cytotoxic drugs kill cancer cells. Breast cancer (BC) has become the most common cancer among women worldwide, posing a severe threat to their lives. Finding new therapeutic targets for BC is the primary task of contemporary physicians. Numerous studies have revealed the close association between caspase-3 expression and BC. Caspase-3 is essential in BC's occurrence, invasion, and metastasis. In addition, Caspase-3 exerts anticancer effects by regulating cell death mechanisms. Traditional Chinese medicine acting through caspase-3 expression is increasingly used in clinical treatment. This review summarizes the biological mechanism of caspase-3 and research progress on BC. It introduces a variety of traditional Chinese medicine related to caspase-3 to provide new ideas for the clinical treatment of BC.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"370-388"},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71482032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resveratrol suppresses NSCLC cell growth, invasion and migration by mediating Wnt/β-catenin pathway via downregulating SIX4 and SPHK2. 白藜芦醇通过下调SIX4和SPHK2介导Wnt/β-catenin通路,抑制NSCLC细胞的生长、侵袭和迁移。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-09-01 Epub Date: 2023-11-15 DOI: 10.1080/1120009X.2023.2281759
Xiaolan Wang, Caixia Liu, Jian Wang, Zexiang Tian

Resveratrol (RSV) has been found to have a cancer-suppressing effect in a variety of cancers, including non-small cell lung cancer (NSCLC). Studies have shown that sine oculis homeobox 4 (SIX4) and sphingosine kinase 2 (SPHK2) are tumour promoters of NSCLC. However, whether RSV regulates SIX4 and SPHK2 to mediate NSCLC cell functions remains unclear. NSCLC cell functions were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay, 5-ethynyl-2'-deoxyuridine (EdU) assay, flow cytometry, transwell assay and wound healing assay. Protein expression levels were detected by western blot. SIX4 and SPHK2 mRNA levels in NSCLC tumour tissues were examined using quantitative real-time PCR. In addition, mice xenograft models were built to explore the impact of RSV on NSCLC tumour growth. RSV inhibited NSCLC cell proliferation, invasion and migration, while facilitated apoptosis. SIX4 and SPHK2 were up-regulated in NSCLC tissues and cells, and their expression was reduced by RSV. Knockdown of SIX4 and SPHK2 suppressed NSCLC cell growth, invasion and migration, and the regulation of RSV on NSCLC cell functions could be reversed by SIX4 and SPHK2 overexpression. RSV inactivated Wnt/β-catenin pathway via decreasing SIX4 and SPHK2 levels. In animal experiments, RSV reduced NSCLC tumour growth in vivo. RSV repressed NSCLC malignant process by decreasing SIX4 and SPHK2 levels to restrain the activity of Wnt/β-catenin pathway.

白藜芦醇(RSV)已被发现对包括非小细胞肺癌(NSCLC)在内的多种癌症具有抑癌作用。研究表明,sine oculis homobox 4 (SIX4)和SPHK2 (SPHK2)是NSCLC的肿瘤启动子。然而,RSV是否调控SIX4和SPHK2介导NSCLC细胞功能尚不清楚。采用3-(4,5-二甲基噻唑-2-酰基)-2,5-二苯基- 2h -溴化四唑(MTT)法、5-乙基-2'-脱氧尿苷(EdU)法、流式细胞术、transwell法和伤口愈合法评估NSCLC细胞功能。western blot检测蛋白表达水平。采用实时荧光定量PCR检测NSCLC肿瘤组织中SIX4和SPHK2 mRNA水平。此外,建立小鼠异种移植模型,探讨RSV对NSCLC肿瘤生长的影响。RSV抑制NSCLC细胞增殖、侵袭和迁移,促进细胞凋亡。SIX4和SPHK2在NSCLC组织和细胞中表达上调,RSV使其表达降低。SIX4和SPHK2的下调可抑制NSCLC细胞的生长、侵袭和迁移,RSV对NSCLC细胞功能的调节可通过SIX4和SPHK2的过表达而逆转。RSV通过降低SIX4和SPHK2水平灭活Wnt/β-catenin通路。在动物实验中,RSV在体内降低了NSCLC肿瘤的生长。RSV通过降低SIX4和SPHK2水平来抑制Wnt/β-catenin通路的活性,从而抑制NSCLC的恶性过程。
{"title":"Resveratrol suppresses NSCLC cell growth, invasion and migration by mediating Wnt/β-catenin pathway via downregulating SIX4 and SPHK2.","authors":"Xiaolan Wang, Caixia Liu, Jian Wang, Zexiang Tian","doi":"10.1080/1120009X.2023.2281759","DOIUrl":"10.1080/1120009X.2023.2281759","url":null,"abstract":"<p><p>Resveratrol (RSV) has been found to have a cancer-suppressing effect in a variety of cancers, including non-small cell lung cancer (NSCLC). Studies have shown that sine oculis homeobox 4 (SIX4) and sphingosine kinase 2 (SPHK2) are tumour promoters of NSCLC. However, whether RSV regulates SIX4 and SPHK2 to mediate NSCLC cell functions remains unclear. NSCLC cell functions were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay, 5-ethynyl-2'-deoxyuridine (EdU) assay, flow cytometry, transwell assay and wound healing assay. Protein expression levels were detected by western blot. SIX4 and SPHK2 mRNA levels in NSCLC tumour tissues were examined using quantitative real-time PCR. In addition, mice xenograft models were built to explore the impact of RSV on NSCLC tumour growth. RSV inhibited NSCLC cell proliferation, invasion and migration, while facilitated apoptosis. SIX4 and SPHK2 were up-regulated in NSCLC tissues and cells, and their expression was reduced by RSV. Knockdown of SIX4 and SPHK2 suppressed NSCLC cell growth, invasion and migration, and the regulation of RSV on NSCLC cell functions could be reversed by SIX4 and SPHK2 overexpression. RSV inactivated Wnt/β-catenin pathway <i>via</i> decreasing SIX4 and SPHK2 levels. In animal experiments, RSV reduced NSCLC tumour growth <i>in vivo</i>. RSV repressed NSCLC malignant process by decreasing SIX4 and SPHK2 levels to restrain the activity of Wnt/β-catenin pathway.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"411-421"},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Chemotherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1